AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
AIM ImmunoTech (NYSE American: AIM) has released a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, the company's Consulting Medical Officer and founder of the Hunter-Hopkins Center. The segment focuses on the results from AIM's Phase 2 study of Ampligen® for Post-COVID fatigue condition (AMP-518). Dr. Lapp, a Key Opinion Leader with over 25 years of experience treating Chronic Fatigue Syndrome and Fibromyalgia, discusses the study's findings regarding efficacy and safety.
AIM ImmunoTech (NYSE American: AIM) ha rilasciato un segmento di Collegamento KOL Virtual Investor che presenta Dr. Charles Lapp, il Medical Officer consulente dell'azienda e fondatore del Hunter-Hopkins Center. Il segmento si concentra sui risultati dello studio Fase 2 di AIM su Ampligen® per la condizione di affaticamento post-COVID (AMP-518). Il Dott. Lapp, un Key Opinion Leader con oltre 25 anni di esperienza nel trattamento della sindrome da affaticamento cronico e della fibromialgia, discute le scoperte dello studio riguardo all'efficacia e alla sicurezza.
AIM ImmunoTech (NYSE American: AIM) ha lanzado un segmento de Conexión KOL para Inversores Virtuales que presenta al Dr. Charles Lapp, el Oficial Médico Consultor de la empresa y fundador del Hunter-Hopkins Center. El segmento se centra en los resultados del estudio de Fase 2 de AIM sobre Ampligen® para la condición de fatiga post-COVID (AMP-518). El Dr. Lapp, un Líder de Opinión Clave con más de 25 años de experiencia en el tratamiento del Síndrome de Fatiga Crónica y la Fibromialgia, comenta los hallazgos del estudio sobre la eficacia y la seguridad.
AIM ImmunoTech (NYSE American: AIM)는 Dr. Charles Lapp, 회사의 상담 임상 의사이자 Hunter-Hopkins 센터의 창립자를 특징으로 하는 가상 투자자 KOL 연결 세그먼트를 발표했습니다. 이 세그먼트는 AIM의 Ampligen®에 대한 2상 연구 결과를 다룹니다. Lapp 박사는 만성 피로 증후군과 섬유근육통 치료에 25년 이상의 경험을 가진 주요 의견 리더로, 연구 결과의 효능과 안전성에 대해 논의합니다.
AIM ImmunoTech (NYSE American: AIM) a publié un segment de connexion KOL pour investisseurs virtuels présentant le Dr Charles Lapp, Médecin Consultant de l'entreprise et fondateur du Hunter-Hopkins Center. Le segment met l'accent sur les résultats de l'étude de Phase 2 d'AIM concernant Ampligen® pour l'état de fatigue post-COVID (AMP-518). Le Dr Lapp, un Leader d'Opinion Clé avec plus de 25 ans d'expérience dans le traitement du syndrome de fatigue chronique et de la fibromyalgie, discute des résultats de l'étude sur l'efficacité et la sécurité.
AIM ImmunoTech (NYSE American: AIM) hat ein Segment zur virtuellen Anleger-KOL-Verbindung veröffentlicht, das Dr. Charles Lapp, den beratenden medizinischen Offizier des Unternehmens und Gründer des Hunter-Hopkins Centers, vorstellt. Das Segment konzentriert sich auf die Ergebnisse von AIMs Phase-2-Studie zu Ampligen® bei der Post-COVID-Ermüdungszustands (AMP-518). Dr. Lapp, ein Key Opinion Leader mit über 25 Jahren Erfahrung in der Behandlung des Chronic Fatigue Syndrome und Fibromyalgie, diskutiert die Ergebnisse der Studie zur Wirksamkeit und Sicherheit.
- None.
- None.
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here
OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, AIM’s Consulting Medical Officer. Dr. Lapp is also the founder of the Hunter-Hopkins Center in Charlotte, N.C., and a Key Opinion Leader who has been treating Chronic Fatigue Syndrome and Fibromyalgia for over 25 years.
As part of the segment, Dr. Lapp discussed results from AIM’s Phase 2 study evaluating the efficacy and safety of Ampligen® as a potential therapeutic for people with the Post-COVID condition of fatigue (“AMP-518”; NCT05592418).
The Virtual Investor KOL Connect Segment can be accessed here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
FAQ
What is AIM ImmunoTech's latest Phase 2 study about (NYSE: AIM)?
Who is discussing AIM ImmunoTech's Phase 2 study results in the Virtual Investor KOL Connect?
What condition is Ampligen® being studied for in AIM ImmunoTech's AMP-518 trial?
